18 September 2026
European Medicines Agency: EMA concludes review of ipidacrine-containing medicines
EMA’s human medicines committee (CHMP) has finalised its review of medicines containing ipidacrine, which are used in adults to treat different conditions affecting the nervous system.
The Committee recommended restricting and better defining the approved uses of the medicines. The medicines can now only be used to relieve symptoms of specific conditions leading to nerve damage in one or more nerves (mononeuropathies and polyneuropathies), but no longer for neuritis, polyneuritis, polyradiculoneuropathy and myasthenic syndrome. They can also be used for the symptomatic treatment of Alzheimer's disease and intestinal atony (a lack of muscle contraction in the gut, resulting in problems with its movement), as an additional symptomatic treatment in certain patients recovering from stroke or traumatic brain injury, and in patients with myasthenia gravis (a disease that causes muscle weakness).
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Changes to the Guidance document “Import of a human medicinal product according to art. 14 para. 2 and 3 TPA (parallel import)”